Molecular aspects of upper tract urothelial carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 1, 2014, Pages 28.e11-28.e20

  Patel, Nilay ^a   Arya, Manit ^b   Muneer, Asif ^b   Powles, Tom ^c   Sullivan, Mark ^a   Hines, John ^b   Kelly, John ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cancer; Genetics; Molecular; Transitional; Upper tract; Urothelial carcinoma

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; AURORA A KINASE; BIOLOGICAL MARKER; CAVEOLIN 1; CELL ADHESION MOLECULE; CETUXIMAB; CYCLOOXYGENASE 2; DOVITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GEFITINIB; GELATINASE A; GELATINASE B; GLUCOSE REGULATED PROTEIN 78; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; LAPATINIB; PARVIN BETA; PROTEIN P27; PROTEIN P53; STATHMIN; SUNITINIB; SURVIVIN; TEMSIROLIMUS; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ANGIOGENESIS; BLADDER CARCINOMA; CANCER PROGNOSIS; CELL CYCLE REGULATION; CELL HYPOXIA; ENVIRONMENTAL FACTOR; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC SUSCEPTIBILITY; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; INTERSTITIAL NEPHRITIS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RARE DISEASE; REVIEW; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; TREATMENT PLANNING; TUMOR INVASION; ANIMAL; ANOXIA; CARCINOMA; CELL ADHESION; CELL CYCLE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PROGNOSIS; URINARY TRACT; URINARY TRACT TUMOR; UROTHELIUM;

ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA; CELL ADHESION; CELL CYCLE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PROGNOSIS; SIGNAL TRANSDUCTION; URINARY TRACT; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 84890807150     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.10.002     Document Type: Review

References (60)

1. Roupret M, Zigeuner R, Palou J, et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas. [2011 update]. Eur Urol 2011;59:584-94.
2. Raman J.D., Ng C.K., Scherr D.S., et al. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol 2010, 57:1072-1079.
3. Ouzzane A., Colin P., Xylinas E., et al. Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol 2011, 60:1258-1265.
4. Margulis V., Shariat S.F., Matin S.F., et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009, 115:1224-1233.
5. Rink M., Ehdaie B., Cha E.K., et al. Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. Eur Urol 2012, 10.1016/j.eururo.2012.02.018.
6. Hellenthal N.J., Shariat S.F., Margulis V., et al. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol 2009, 182:900-906.
7. Colin P., Koenig P., Ouzzane A., et al. Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. Brit J Urol Int 2009, 104:1436-1440.
8. Laing C., Hamour S., Sheaff M., Miller R., Woolfson R. Chinese herbal uropathy and nephropathy. Lancet 2006, 368:338.
9. Stiborová M., Frei E., Schmeiser H.H. Biotransformation enzymes in development of renal injury and urothelial cancer caused by aristolochic acid. Kidney Int 2008, 73:1209-1211.
10. Slade N., Moll U.M., Brdar B., Zorić A., Jelaković B. p53 mutations as fingerprints for aristolochic acid: an environmental carcinogen in endemic (Balkan) nephropathy. Mutat Res 2009, 663:1-6.
11. Toncheva D.I., Ahsen Von N., Atanasova S.Y., Dimitrov T.G., Armstrong V.W., Oellerich M. Identification of NQO1 and GSTs genotype frequencies in Bulgarian patients with Balkan endemic nephropathy. J Nephrol 2004, 17:384-389.
12. Roupret M., Cancel-Tassin G., Comperat E., et al. Phenol sulfotransferase SULT1A1*2 allele and enhanced risk of upper urinary tract urothelial cell carcinoma. Cancer Epidemiol Biomarker Prev 2007, 16:2500-2503.
13. Rigola M.A., Fuster C., Casadevall C., et al. Comparative genomic hybridization analysis of transitional cell carcinomas of the renal pelvis. Cancer Genet Cytogenet 2001, 127:59-63.
14. Czerniak B., Chaturvedi V., Li L., et al. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene 1999, 18:1185-1196.
15. Wu C.-F., Pang S.-T., Shee J.-J., et al. Identification of genetic alterations in upper urinary tract urothelial carcinoma in end-stage renal disease patients. Genes Chromosomes Cancer 2010, 49:928-934.
16. Sijmons R.H., Kiemeney L.A., Witjes J.A., Vasen H.F. Urinary tract cancer and hereditary nonpolyposis colorectal cancer: risks and screening options. J Uro 1998, 160:466-470.
17. Skeldon S.C., Semotiuk K., Aronson M., et al. Patients with lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. Eur Urol 2012, 10.1016/j.eururo.2012.07.047.
18. Vilar E., Gruber S.B. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol 2010, 7:153-162.
19. Roupret M., Yates D.R., Comperat E., Cussenot O. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (Lynch syndrome) tumor spectrum. Eur Urol 2008, 54:1226-1236.
20. Catto J.W., Azzouzi A.R., Rehman I., et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 2005, 23:2903-2910.
21. Valeri N., Gasparini P., Fabbri M., et al. Modulation of mismatch repair and genomic stability by miR-155. Proc Nat Acad Sci 2010, 107:6982-6987.
22. Catto J.W.F., Azzouzi A.-R., Amira N., et al. Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. Oncogene 2003, 22:8699-8706.
23. Hartmann A., Dietmaier W., Hofstaumldter F., Burgart L.J., Cheville J.C., Blaszyk H. Urothelial carcinoma of the upper urinary tract: inverted growth pattern is predictive of microsatellite instability. Hum Pathol 2003, 34:222-227.
24. Rouprêt M., Fromont G., Azzouzi A.-R., et al. Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. Urology 2005, 65:1233-1237.
25. Kamai T., Takagi K., Asami H., Ito Y., Arai K., Yoshida K.I. Prognostic significance of p27Kip1 and Ki-67 expression in carcinoma of the renal pelvis and ureter. Brit J Urol Int 2000, 86:14-19.
26. Zigeuner R., Tsybrovskyy O., Ratschek M., Rehak P., Lipsky K., Langner C. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. Urology 2004, 63:1079-1083.
27. Yeh H.-C., Huang C.-H., Yang S.-F., et al. Nuclear factor-κB activation predicts an unfavourable outcome in human upper urinary tract urothelial carcinoma. Brit J Urol Int 2010, 106:1223-1229.
28. Scarpini S., Rouprêt M., Renard-Penna R., Camparo P., Cussenot O., Compérat E. Impact of the expression of Aurora-A, p53, and Mib-1 on the prognosis of urothelial carcinomas of the upper urinary tract. Urology 2011, 10.1016/j.urolonc.2009.12.003.
29. Akao J., Matsuyama H., Yamamoto Y., Sasaki K., Naito K. Chromosome 20q13.2 gain may predict intravesical recurrence after nephroureterectomy in upper urinary tract urothelial tumors. Clin Cancer Res 2006, 12:7004-7008.
30. Lin W.C., Chen S.C., Hu F.C., et al. Expression of stathmin in localized upper urinary tract urothelial carcinoma: correlations with prognosis. Urology 2011, 74:1264-1269.
31. Cho D.S., Yim H., Cho K.S., et al. Impact of caveolin-1 expression on the prognosis of transitional cell carcinoma of the upper urinary tract. J Korean Med Sci 2008, 23:296-301.
32. Md I.G.J., Md S.H.K., Md H.G.J., et al. Prognostic value of apoptosis-related markers in urothelial cancer of the upper urinary tract. Hum Pathol 2009, 40:668-677.
33. Jeon H.G., Jeong I.G., Bae J., et al. Expression of Ki-67 and COX-2 in patients with upper urinary tract urothelial carcinoma. Urology 2011, 76:513.e7-513.e12.
34. Jou Y.C., Tung C.L., Tsai Y.S., et al. Prognostic relevance of prothymosin-α expression in human upper urinary tract transitional cell carcinoma. Urology 2011, 74:951-957.
35. Zhang Z, Zhang Z, Furge KA, et al. Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder. Bioorg Med Chem Med Genomics 2010, 3:58.
36. Nakanishi K., Ogata S., Matsuo H., et al. Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. Virchows Arch 2007, 451:681-690.
37. Uematsu K., Uematsu K., Ogata S., et al. Glucose-regulated protein 78 expression in urothelial carcinoma of the upper urinary tract. Brit J Urol Int 2010, 106:873-878.
38. Qian C.-N., Furge K.A., Knol J., et al. Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models. Cancer Res 2009, 69:8256-8264.
39. van Oers J.M.M., Zwarthoff E.C., Rehman I., et al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol 2009, 55:650-658.
40. Ishida M., Mikami S., Kikuchi E., et al. Activation of the aryl hydrocarbon receptor pathway enhances cancer cell invasion by upregulating the MMP expression and is associated with poor prognosis in upper urinary tract urothelial cancer. Carcinogenesis 2010, 31:287-295.
41. Miyata Y., Kanda S., Nomata K., Eguchi J., Kanetake H. Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract. J Urol 2005, 173:56-60.
42. Langner C., Gross C., Rehak P., Ratschek M., Rüschoff J., Zigeuner R. HER2 protein overexpression and gene amplification in upper urinary tract transitional cell carcinoma: systematic analysis applying tissue microarray technique. Urology 2005, 65:176-180.
43. Nakanishi K., Hiroi S., Tominaga S., et al. Expression of hypoxia-inducible factor-1 protein predicts survival in patients with transitional cell carcinoma of the upper urinary tract. Clin Cancer Res 2005, 11:2583-2590.
44. Ke H.-L., Wei Y.-C., Yang S.-F., et al. Overexpression of hypoxia-inducible factor-1α predicts an unfavorable outcome in urothelial carcinoma of the upper urinary tract. Int J Urol 2008, 15:200-205.
45. Fromont G., Rouprêt M., Amira N., et al. Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma. Eur Urol 2005, 48:764-770.
46. Inoue K., Kamada M., Slaton J.W., et al. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res 2002, 8:1863-1870.
47. Wu C.-F., Wu C.-F., Ng K.-F., et al. Expression of parvin-β is a prognostic factor for patients with urothelial cell carcinoma of the upper urinary tract. Brit J Cancer 2010, 103:852-860.
48. Miyata Y., Kanda S., Nomata K., Hayashida Y., Kanetake H. Expression of metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: correlation with tumor stage and survival. Urology 2004, 63:602-608.
49. Kosaka T., Kikuchi E., Mikami S., et al. Expression of Snail in upper urinary tract urothelial carcinoma: prognostic significance and implications for tumor invasion. Clin Cancer Res 2010, 16:5814-5823.
50. Ohtsuka Y., Kawakami S., Fujii Y., et al. Loss of uroplakin III expression is associated with a poor prognosis in patients with urothelial carcinoma of the upper urinary tract. Brit J Urol Int 2006, 97:1322-1326.
51. Zhou H., Huang H.Y., Shapiro E., et al. Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies. Carcinogenesis 2012, 33:770-780.
52. Lindgren D., Frigyesi A., Gudjonsson S., et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 2010, 70:3463-3472.
53. Lindgren D., Sjödahl G., Lauss M., et al. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS ONE 2012, 7:e38863.
54. Tomlinson D.C., Baxter E.W., Loadman P.M., Hull M.A., Knowles M.A. FGFR1-induced epithelial to mesenchymal transition through MAPK/PLCγ/COX-2-mediated mechanisms. PLoS ONE 2012, 7:e38972.
55. Sjödahl G., Lauss M., Gudjonsson S., et al. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS ONE 2011, 6:e18583.
56. Daniele G, Corral J, Molife LR, Bono JS FGF receptor inhibitors: role in cancer therapy. Curr Oncol Rep 2012, 14:111-119.
57. Ching C.B., Hansel D.E. Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway. Lab Invest 2010, 90:1406-1414.
58. Richter S., Sridhar S.S. New directions for biologic targets in urothelial carcinoma. Mol Cancer Ther 2012, 11:1226-1235.
59. van der Aa M.N.M., Zwarthoff E.C., Steyerberg E.W., et al. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (cost-effectiveness of follow-up of urinary bladder cancer trial [CEFUB]). Eur Urol 2009, 55:659-668.
60. Audenet F, Colin P, Yates DR et al.: A proportion of hereditary upper urinary tract urothelial carcinomas are misclassified as sporadic according to a multi-institutional database analysis: proposal of patient-specific risk identification tool. Brit J Urol Int 2012; http://dx.doi.org/10.1111/j.1464-410X.2012.11298.x.